Drug Trial Radar · NCT03814746
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
253
Actual
Start
Jul 26, 2019
Primary completion
Aug 31, 2022
Study completion Nov 5, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.
Conditions
- Sickle Cell Disease (SCD)
Interventions
Crizanlizumab (SEG101)Drug
Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion. IV.
PlaceboDrug
Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Vaso-occlusive Crisis (VOC) Events Leading to a Healthcare VisitTime frame: 1 year
Locations
58 sites in 21 countries. Site status is shown where the registry gives one.
Childrens Healthcare of Atlanta
Atlanta, Georgia
Boston Medical Center
Boston, Massachusetts
Levine Cancer Insitute Carolinas Healthcare System
Charlotte, North Carolina
Univ of Tenn Health Sciences Ctr
Memphis, Tennessee
U of TX Health Science Ct
Houston, Texas
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Brussels, Brussels Capital, Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Belém, Pará, Brazil
Novartis Investigative Site
Recife, Pernambuco, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montería, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Valledupar, Cesar Department, Colombia
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Accra, Ghana
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Thessaloniki, Greece
Novartis Investigative Site
Bhubaneswar, Odisha, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Verona, VR, Italy
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.